We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-0.11%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.97B
AUM Growth
-$817M
Cap. Flow
-$41.1M
Cap. Flow %
-0.52%
Top 10 Hldgs %
77.13%
Holding
94
New
12
Increased
15
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$71.2M
2
BCYC
Bicycle Therapeutics
BCYC
+$67M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$43.3M
4
ABCL icon
AbCellera Biologics
ABCL
+$23.6M
5
DNLI icon
Denali Therapeutics
DNLI
+$21.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$242M
2
IMCR icon
Immunocore
IMCR
+$69M
3
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$20.9M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$14.6M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPT
51
DELISTED
Opthea Limited American Depositary Shares
OPT
$8.95M 0.11%
2,177,826
-410,819
-16% -$1.29M
NMRA icon
52
Neumora Therapeutics
NMRA
$306M
$8.72M 0.11%
+633,851
New +$10.2M
LONA
53
LeonaBio Inc
LONA
$72.4M
$8.64M 0.11%
315,381
– –
DYN icon
54
Dyne Therapeutics
DYN
$4.87B
$8.09M 0.1%
+285,000
New +$6.45M
PRAX icon
55
Praxis Precision Medicines
PRAX
$10.5B
$8.03M 0.1%
131,533
– –
SAGE
56
DELISTED
Sage Therapeutics
SAGE
$7.63M 0.1%
+407,217
New +$9.39M
SGMT icon
57
Sagimet Biosciences
SGMT
$637M
$7.49M 0.09%
1,381,898
-74,620
-5% -$536K
PRME icon
58
Prime Medicine
PRME
$615M
$7.2M 0.09%
1,028,466
– –
DSGN icon
59
Design Therapeutics
DSGN
$938M
$6.7M 0.08%
1,662,120
+162,120
+11% +$433K
TNGX icon
60
Tango Therapeutics
TNGX
$4.03B
$5.96M 0.07%
750,000
– –
HOOK
61
DELISTED
HOOKIPA Pharma
HOOK
$5.79M 0.07%
812,815
– –
MRSN
62
DELISTED
Mersana Therapeutics
MRSN
$4.87M 0.06%
43,445
– –
MIRM icon
63
Mirum Pharmaceuticals
MIRM
$5.87B
$4.78M 0.06%
190,476
– –
TLIS
64
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$4.45M 0.06%
508,323
– –
PCVX icon
65
Vaxcyte
PCVX
$9.32B
$3.34M 0.04%
48,885
– –
IPSC icon
66
Century Therapeutics
IPSC
$375M
$3.33M 0.04%
797,460
– –
ALPN
67
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.23M 0.04%
+81,578
New +$2.41M
FDMT icon
68
4D Molecular Therapeutics
FDMT
$875M
$3.19M 0.04%
+100,000
New +$2.55M
CYPH
69
Cypherpunk Technologies Inc
CYPH
$153M
$3.12M 0.04%
1,172,175
– –
CMPX icon
70
Compass Therapeutics
CMPX
$432M
$3.08M 0.04%
1,557,630
– –
NAMS icon
71
NewAmsterdam Pharma
NAMS
$3.33B
$2.29M 0.03%
+96,827
New +$1.97M
VTVT icon
72
vTv Therapeutics
VTVT
$132M
$2.29M 0.03%
+97,314
New +$1.24M
KALA icon
73
KALA BIO
KALA
$15.9M
$2.12M 0.03%
5,332
– –
ALGS icon
74
Aligos Therapeutics
ALGS
$41.7M
$2.03M 0.03%
83,056
– –
ELVN icon
75
Enliven Therapeutics
ELVN
$4.38B
$2.02M 0.03%
+114,833
New +$1.76M
1 2
3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2024 Portfolio in Review

As of Q1 2024, Julian Baker held 94 positions worth $7.97B, down 9.3% from $8.79B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Julian Baker's Q1 2024 filing shows 12 new, 15 increased, 7 reduced and 7 closed positions. Its largest new stake was Fate Therapeutics: 1,818,181 shares worth $13.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $242M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q1 2024 buy was Fate Therapeutics: 1,818,181 shares worth $13.3M.
  • Julian Baker added most to Revolution Medicines in Q1 2024, an estimated $71.2M increase.
  • Julian Baker's biggest Q1 2024 reduction was Immunocore, cutting an estimated $69M.
  • Julian Baker fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $242M.
  • Julian Baker's ten largest holdings make up 77% of its $7.97B portfolio in Q1 2024.
  • Julian Baker opened 12 new positions and closed 7 in Q1 2024.
  • Julian Baker's portfolio value fell 9.3% quarter-over-quarter to $7.97B.

Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.